At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 144 enrolled
Drug / intervention
Fulvestrantdrug
Likely dose
Fulvestrant 250 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study to Evaluate the Efficacy and Tolerability of Fulvestrant 250mg, 250mg Plus 250mg Loading Regimen and 500mg in Postmenopausal Women With ER +ve Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy
In Brief
A Phase 2 clinical trial evaluating Fulvestrant for Advanced Breast Cancer and Metastatic Breast Cancer. Completed, enrolled 144 participants across 34 sites in 8 countries.
Detailed Summary
This study will assess the relationship between fulvestrant dose and efficacy in postmenopausal women with oestrogen receptor positive advanced breast cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Breast Cancer, Metastatic Breast Cancer
CountriesBelgium, Canada, Czechia, France, Hungary, Poland, Romania, Turkey (Türkiye)
Collaborators--
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 2006
Enrollment StartMay 2006
Primary CompletionJun 2008
Study CompletionMar 2019
TodayJul 2026
First PostedApr 12, 2006
Enrollment StartMay 30, 2006
Primary CompletionJun 13, 2008
Study CompletionMar 13, 2019
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 20.2 years ago
Interventions
Fulvestrantdrug
intramuscular injection 250 mg \& 500 mg